Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-08-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanghai Medicilon Inc. regarding the approval of the company's 2022 semi-annual report and related special reports on the use of raised funds. It includes voting results and confirms compliance with legal and regulatory requirements. The document does not contain the actual semi-annual financial report or detailed financial data but rather announces the approval and references the reports published elsewhere (on the Shanghai Stock Exchange website). The document length is short (1395 characters) and serves as an official announcement of meeting resolutions and approvals, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2022-08-22 Chinese
美迪西：前次募集资金使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Shanghai Medicilon Inc. It includes specifics on the amount raised, management and storage of funds, actual usage, investment projects, and economic benefits realized. The document references compliance with regulations from the China Securities Regulatory Commission and includes financial figures and project details up to June 30, 2022. It is not an announcement of a report but the report itself, containing substantive financial data and analysis related to the use of capital raised. This fits the category of a Capital/Financing Update (CAP), as it focuses on the use and management of fundraising proceeds rather than a full annual or interim financial report or other categories.
2022-08-22 Chinese
美迪西：2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report." It covers the period from January to June 2022, as indicated by the term "报告期" (reporting period) and the dates mentioned. The content includes detailed financial data such as revenue, net profit, cash flow, earnings per share, and management discussion and analysis of business operations and industry context. The document is comprehensive, spanning over 200 pages, and contains actual financial statements and substantive analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data and analysis. It is not merely an announcement or a certification, but a full report. Therefore, the correct classification is IR. H1 2022
2022-08-22 Chinese
美迪西：独立董事关于第三届董事会第八次会议相关事项的独立意见
Regulatory Filings
2022-08-22 Chinese
美迪西：关于董事、高级管理人员亲属短线交易及致歉的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a short-swing trading violation by a director's relative and the company's response, including an apology and remedial measures. It details insider trading compliance issues and regulatory references but does not contain financial statements, earnings data, or report publication information. It is not a full financial report, earnings release, or management discussion. It is a regulatory disclosure about insider trading and compliance, fitting best under Regulatory Filings (RNS). The document length is short and focused on compliance and disclosure of insider trading, not a report or announcement of a report publication.
2022-07-26 Chinese
美迪西：关于向特定对象发行股票发行注册环节反馈意见落实函回复的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the company's response to regulatory feedback from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange (SSE) about a specific share issuance to targeted investors. It discusses the registration process and the company's compliance with feedback but does not contain financial statements or detailed financial data. The document is short (704 characters) and primarily serves as an update on the regulatory process for a capital raising event. Therefore, it is best classified as a Capital/Financing Update (CAP) rather than the actual share issuance report or registration filing.
2022-07-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.